MRVI - Maravai LifeSciences Holdings Inc Stock Price, Fair Value and News

7.59USD-0.08 (-1.04%)Market Closed

Market Summary

USD7.59-0.08

Market Closed

-1.04%

MRVI Stock Price

View Fullscreen

MRVI RSI Chart

MRVI Valuation

Market Cap

1.0B

Price/Earnings (Trailing)

-8.41

Price/Sales (Trailing)

3.47

EV/EBITDA

1.4

Price/Free Cashflow

16.5

MRVI Price/Sales (Trailing)

MRVI Profitability

Operating Margin

48.52%

EBT Margin

213.79%

Return on Equity

-28.56%

Return on Assets

-8%

Free Cashflow Yield

6.06%

MRVI Fundamentals

MRVI Revenue

Revenue (TTM)

288.9M

Rev. Growth (Yr)

-63.78%

Rev. Growth (Qtr)

10.88%

MRVI Earnings

Earnings (TTM)

-119.0M

Earnings Growth (Yr)

-381.55%

Earnings Growth (Qtr)

-1.5K%

Breaking Down MRVI Revenue

Last 7 days

-0.3%

Last 30 days

-9.0%

Last 90 days

17.3%

Trailing 12 Months

-42.6%

How does MRVI drawdown profile look like?

MRVI Financial Health

Current Ratio

Debt/Equity

1.24

Debt/Cashflow

0.24

MRVI Investor Care

Shares Dilution (1Y)

0.28%

Diluted EPS (TTM)

-0.9

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	717.7M	543.9M	419.5M	288.9M
2022	895.3M	920.3M	906.7M	883.0M
2021	381.3M	552.2M	669.1M	799.2M
2020	178.4M	213.6M	248.9M	284.1M
2019	0	0	0	143.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Maravai LifeSciences Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	burch andrew	sold (taxes)	-135,907	8.11	-16,758	see remarks
Mar 15, 2024	dolan christine	sold (taxes)	-41,449	7.7	-5,383	see remarks
Mar 15, 2024	herde kevin	sold (taxes)	-66,404	7.7	-8,624	chief financial officer
Mar 15, 2024	hull carl	sold (taxes)	-135,212	7.7	-17,560	see remarks
Mar 15, 2024	leddy peter michael	sold (taxes)	-51,697	7.7	-6,714	see remarks
Mar 15, 2024	oreshack kurt	sold (taxes)	-35,042	7.7	-4,551	general counsel
Mar 15, 2024	buzzeo rebecca	sold (taxes)	-33,618	7.7	-4,366	see remarks
Feb 15, 2024	hull carl	sold (taxes)	-58,794	5.48	-10,729	see remarks
Feb 15, 2024	herde kevin	sold (taxes)	-14,598	5.48	-2,664	chief financial officer
Feb 15, 2024	oreshack kurt	sold (taxes)	-12,724	5.48	-2,322	general counsel

Which funds bought or sold MRVI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Simplicity Wealth,LLC	new	-	256,745	256,745	0.01%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	79,000	371,000	-%
Apr 23, 2024	Global Retirement Partners, LLC	added	58.41	825	1,552	-%
Apr 23, 2024	AMALGAMATED BANK	added	11.37	61,000	189,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	reduced	-1.45	-17,105	31,145	-%
Apr 19, 2024	Red Tortoise LLC	sold off	-100	-2,070	-	-%
Apr 19, 2024	State of Alaska, Department of Revenue	sold off	-100	-2,564,000	-	-%
Apr 19, 2024	NORDEN GROUP LLC	new	-	289,962	289,962	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	sold off	-100	-530	-	-%
Apr 18, 2024	SJS Investment Consulting Inc.	unchanged	-	8.00	35.00	-%

Are Funds Buying or Selling MRVI?

Are funds buying MRVI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRVI

No. of Funds

Unveiling Maravai LifeSciences Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 28, 2024	12 west capital management lp	8.8%	11,602,988	SC 13G/A
Feb 14, 2024	12 west capital management lp	8.78%	11,602,988	SC 13G
Feb 14, 2024	12 west capital management lp	8.78%	11,602,988	SC 13G
Feb 13, 2024	vanguard group inc	7.57%	10,003,894	SC 13G/A
Feb 08, 2024	maravai life sciences holdings 2, llc	8.63%	21,681,033	SC 13G/A
Jan 05, 2024	millennium management llc	4.5%	6,007,149	SC 13G/A
Nov 07, 2023	massachusetts financial services co /ma/	4.6%	6,058,247	SC 13G/A
Oct 26, 2023	millennium management llc	5.3%	6,975,927	SC 13G
Feb 14, 2023	select equity group, l.p.	1.9%	2,524,793	SC 13G/A
Feb 09, 2023	vanguard group inc	7.90%	10,389,979	SC 13G/A

Recent SEC filings of Maravai LifeSciences Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	ARS	ARS
Apr 25, 2024	DEF 14A	DEF 14A
Apr 16, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Feb 29, 2024	10-K	Annual Report

Peers (Alternatives to Maravai LifeSciences Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.12	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Maravai LifeSciences Holdings Inc News

Latest updates

Maravai LifeSciences Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																	(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	10.9%	74.00	67.00	69.00	79.00	205	191	243	244	228	205	218	148	98.00	88.00	47.00	51.00	-
Cost Of Revenue	-4.3%	35.00	37.00	43.00	34.00	53.00	38.00	37.00	40.00	39.00	32.00	38.00	31.00	23.00	20.00	21.00	15.00	-
Costs and Expenses	-1.2%	81.00	82.00	81.00	76.00	95.00	74.00	62.00	77.00	74.00	49.00	64.00	57.00	67.00	42.00	39.00	16.00	-
S&GA Expenses	-1.0%	38.00	39.00	35.00	39.00	37.00	31.00	28.00	33.00	26.00	27.00	25.00	23.00	42.00	21.00	16.00	16.00	-
R&D Expenses	5.7%	5.00	4.00	4.00	4.00	5.00	5.00	4.00	4.00	9.00	2.00	2.00	2.00	2.00	2.00	2.00	4.00	-
EBITDA Margin	800.9%	2.34*	0.26*	0.43*	0.58*	0.66*	0.69*	0.72*	0.72*	0.71*	-	-	-	-	-	-	-	-
Interest Expenses	32.3%	15.00	12.00	7.00	12.00	10.00	3.00	4.00	3.00	7.00	8.00	8.00	8.00	9.00	7.00	7.00	7.00	-
Income Taxes	14129.8%	766	-5.46	-1.42	-3.17	8.00	14.00	18.00	20.00	18.00	19.00	11.00	14.00	0.00	-0.36	-0.76	4.00	-
Earnings Before Taxes	3291.1%	656	-20.56	-13.36	-4.52	96.00	114	175	167	145	151	146	89.00	15.00	39.00	1.00	28.00	-
EBT Margin	1461.8%	2.14*	0.14*	0.35*	0.53*	0.62*	0.66*	0.69*	0.68*	0.66*	0.60*	0.52*	0.38*	0.29*	-0.02*	-0.03*	-0.03*	-0.04*
Net Income	-1539.7%	-105	-6.46	-6.54	-0.07	38.00	44.00	71.00	67.00	56.00	54.00	49.00	23.00	-	39.00	1.00	23.00	-
Net Income Margin	-803.5%	-0.41*	0.06*	0.14*	0.21*	0.25*	0.26*	0.27*	0.25*	0.23*	0.13*	0.16*	0.23*	0.31*	-0.02*	-0.02*	-0.03*	-0.03*
Free Cashflow	-442.4%	-9.01	-1.66	-5.86	77.00	93.00	104	163	160	53.00	104	161	35.00	71.00	41.00	9.00	6.00	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-34.4%	1,487	2,268	2,264	2,315	2,282	2,249	2,172	2,043	1,918	1,895	1,601	1,352	1,271
Current Assets	-0.1%	700	701	699	766	848	836	759	619	740	687	644	426	332
Cash Equivalents	-0.8%	575	580	580	628	632	617	551	431	551	548	375	248	236
Inventory	4.6%	51.00	49.00	47.00	55.00	43.00	62.00	60.00	51.00	52.00	56.00	48.00	47.00	33.00
Net PPE	-	-	-	-	-	53.00	48.00	47.00	48.00	46.00	108	105	105	101
Goodwill	0%	326	326	326	327	284	284	284	284	153	153	153	224	224
Liabilities	-49.3%	698	1,375	1,367	1,415	1,377	1,407	1,398	1,389	1,373	1,441	1,268	1,142	1,116
Current Liabilities	11.8%	87.00	78.00	75.00	125	110	116	113	87.00	94.00	114	165	165	131
Long Term Debt	-0.2%	519	520	520	521	522	523	524	524	525	526	527	528	529
LT Debt, Current	0%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00
LT Debt, Non Current	-0.2%	519	520	520	521	522	523	524	524	525	526	527	528	529
Shareholder's Equity	-19.7%	417	519	898	901	545	842	774	654	545	457	337	214	155
Retained Earnings	-27.1%	286	392	398	405	405	367	323	251	185	129	75.00	26.00	1.00
Additional Paid-In Capital	2.7%	129	125	120	114	138	134	131	129	128	173	118	86.00	85.00
Shares Outstanding	0.0%	132	132	132	132	132	132	132	131	115	109	104	97.00	-
Minority Interest	0.0%	373	373	377	379	360	338	317	272	230	153	142	100	66.00
Float	-	-	-	1,370	-	-	-	3,121	-	-	-	3,745	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-45.0%	7,790	14,166	19,194	85,074	99,335	110,059	164,279	162,304	58,743	105,562	165,939	38,326	79,431	51,428	11,615	9,713	-
Share Based Compensation	-6.5%	9,342	9,987	9,272	5,987	5,995	4,740	4,308	3,627	2,230	3,567	2,383	2,278	21,696	1,849	576	508	-
Cashflow From Investing	16.9%	-12,903	-15,520	-24,157	-69,730	-18,520	-5,847	-1,661	-241,584	-5,656	118,628	-4,533	-2,784	-8,849	-10,091	-3,059	28,067	-
Cashflow From Financing	-40.0%	470	783	-43,134	-19,209	-66,123	-37,442	-43,411	-40,523	-49,580	-51,284	-34,127	-24,058	40,672	-943	-856	14,339	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,140	-	-	-

MRVI Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 288,945	$ 883,001	$ 799,240
Operating expenses:
Cost of revenue	148,743	168,957	140,561
Selling, general and administrative	151,390	129,259	100,064
Research and development	17,280	18,369	15,219
Change in estimated fair value of contingent consideration	(3,286)	(7,800)	0
Restructuring	6,466	0	0
Gain on sale of business	0	0	(11,249)
Total operating expenses	320,593	308,785	244,595
(Loss) income from operations	(31,648)	574,216	554,645
Other income (expense):
Interest expense	(45,892)	(20,414)	(30,260)
Interest income	27,727	2,338	0
Loss on extinguishment of debt	0	(208)	0
Change in payable to related parties pursuant to the Tax Receivable Agreement	668,886	(4,102)	6,101
Other (expense) income	(1,337)	(358)	279
Income before income taxes	617,736	551,472	530,765
Income tax expense	756,111	60,809	61,515
Net (loss) income	(138,375)	490,663	469,250
Net (loss) income attributable to non-controlling interests	(19,346)	270,458	287,213
Net (loss) income attributable to Maravai LifeSciences Holdings, Inc.	$ (119,029)	$ 220,205	$ 182,037
Net (loss) income per Class A common share attributable to Maravai LifeSciences Holdings, Inc.:
Basic (in usd per share)	$ (0.90)	$ 1.67	$ 1.59
Diluted (in usd per share)	$ (0.90)	$ 1.67	$ 1.56
Weighted average number of Class A common shares outstanding:
Basic (in shares)	131,919	131,545	114,791
Diluted (in shares)	131,919	255,323	257,803

MRVI Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 574,962	$ 632,138
Accounts receivable, net	54,605	138,624
Inventory	51,397	43,152
Prepaid expenses and other current assets	17,830	25,798
Government funding receivable	1,118	8,190
Total current assets	699,912	847,902
Property and equipment, net	162,900	52,694
Goodwill	326,029	283,668
Intangible assets, net	220,987	216,663
Deferred tax assets	0	765,799
Other assets	77,622	115,589
Total assets	1,487,450	2,282,315
Current liabilities:
Accrued expenses and other current liabilities	60,237	53,371
Deferred revenue	3,360	3,088
Current portion of long-term debt	5,440	5,440
Current portion of finance lease liabilities	633	0
Total current liabilities	87,468	110,144
Long-term debt, less current portion	518,707	521,997
Finance lease liabilities, less current portion	31,897	0
Other long-term liabilities	59,494	68,975
Total liabilities	697,566	1,377,072
Commitments and contingencies (Note 9)
Stockholders’ equity:
Additional paid-in capital	128,503	137,898
Retained earnings	285,737	404,766
Total stockholders’ equity attributable to Maravai LifeSciences Holdings, Inc.	416,753	545,218
Non-controlling interest	373,131	360,025
Total stockholders’ equity	789,884	905,243
Total liabilities and stockholders’ equity	1,487,450	2,282,315
Class A Common Stock
Stockholders’ equity:
Common stock	1,322	1,317
Shares of Class B common stock
Stockholders’ equity:
Common stock	1,191	1,237
Nonrelated Party
Current liabilities:
Accounts payable	10,729	5,991
Related Party
Current liabilities:
Accounts payable	7,069	42,254
Payable to related parties pursuant to the Tax Receivable Agreement, less current portion	$ 0	$ 675,956

About Maravai LifeSciences Holdings Inc

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

WEBSITE	maravai.com
INDUSTRY	Biotechnology
EMPLOYEES	660

Maravai LifeSciences Holdings Inc Frequently Asked Questions

What is the ticker symbol for Maravai LifeSciences Holdings Inc? What does MRVI stand for in stocks?

MRVI is the stock ticker symbol of Maravai LifeSciences Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Maravai LifeSciences Holdings Inc (MRVI)?

As of Thu Apr 25 2024, market cap of Maravai LifeSciences Holdings Inc is 1 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRVI stock?

You can check MRVI's fair value in chart for subscribers.

What is the fair value of MRVI stock?

You can check MRVI's fair value in chart for subscribers. The fair value of Maravai LifeSciences Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Maravai LifeSciences Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRVI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Maravai LifeSciences Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether MRVI is over valued or under valued. Whether Maravai LifeSciences Holdings Inc is cheap or expensive depends on the assumptions which impact Maravai LifeSciences Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRVI.

What is Maravai LifeSciences Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, MRVI's PE ratio (Price to Earnings) is -8.41 and Price to Sales (PS) ratio is 3.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRVI PE ratio will change depending on the future growth rate expectations of investors.